更正：关于系统性红斑狼疮患者使用阿尼洛单抗的观点以及临床实践中尚未满足的大量需求

IF 5.1 2区医学 Q1 RHEUMATOLOGY RMD Open Pub Date : 2024-04-01 DOI:10.1136/rmdopen-2023-003270corr1

EULAR

{"title":"更正：关于系统性红斑狼疮患者使用阿尼洛单抗的观点以及临床实践中尚未满足的大量需求","authors":"EULAR","doi":"10.1136/rmdopen-2023-003270corr1","DOIUrl":null,"url":null,"abstract":"Tanaka Y. Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice. RMD Open 2023;9:e003270. doi: 10.1136/rmdopen-2023-003270 Updates have been made to the 2nd paragraph under the following section: Patients with moderate to severe SLE who are unable to achieve at least LLDAS with existing SoC …","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":null,"pages":null},"PeriodicalIF":5.1000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction: Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice\",\"authors\":\"EULAR\",\"doi\":\"10.1136/rmdopen-2023-003270corr1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Tanaka Y. Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice. RMD Open 2023;9:e003270. doi: 10.1136/rmdopen-2023-003270 Updates have been made to the 2nd paragraph under the following section: Patients with moderate to severe SLE who are unable to achieve at least LLDAS with existing SoC …\",\"PeriodicalId\":21396,\"journal\":{\"name\":\"RMD Open\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"RMD Open\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/rmdopen-2023-003270corr1\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"RMD Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/rmdopen-2023-003270corr1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Tanaka Y. Anifrolumab在系统性红斑狼疮患者中的应用及临床实践中尚未满足的高需求观点。doi: 10.1136/rmdopen-2023-003270 对以下部分的第2段进行了更新：中度至重度系统性红斑狼疮患者使用现有的 SoC 无法达到至少 LLDAS ...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Correction: Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice

Tanaka Y. Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice. RMD Open 2023;9:e003270. doi: 10.1136/rmdopen-2023-003270 Updates have been made to the 2nd paragraph under the following section: Patients with moderate to severe SLE who are unable to achieve at least LLDAS with existing SoC …

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

RMD Open RHEUMATOLOGY-

CiteScore

7.30

自引率

6.50%

发文量

205

审稿时长

14 weeks

期刊介绍： RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.